載入...
Obinutuzumab: the more the merrier?
In this issue of Blood, Byrd et al present data from a randomized phase 2 study in which 78 previously untreated patients with chronic lymphocytic leukemia (CLL) received 8 cycles of either 1000 mg (the current standard dose) or 2000 mg of the anti-CD20 monoclonal antibody (mAb) obinutuzumab.(1) The...
Na minha lista:
| 發表在: | Blood |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4705611/ https://ncbi.nlm.nih.gov/pubmed/26744434 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-10-676882 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|